Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Parkinson’s Med Nouriast Fails in PIII Study in US, Europe: Kyowa Kirin
December 14, 2016
- Daiichi Sankyo Links Arms with DarwinHealth on Cancer R&D
December 14, 2016
- Entyvio Delivers Higher Response Rates as 1st Line Biologic
December 13, 2016
- Astellas Europe to Transfer Rights for Pain Med Qutenza to Grünenthal
December 13, 2016
- Eisai’s BACE Inhibitor Cuts Beta Amyloid by 70% at 50 mg Daily
December 13, 2016
- Biogen Japan Seeks Japan Approval for Nusinersen
December 13, 2016
- Aspen Japan Starting on Right Foot on AG Biz: GSK Japan President
December 13, 2016
- Development of Novel Myeloid Leukemia Drug Gilteritinib Makes Progress: Astellas
December 12, 2016
- Mitsubishi Tanabe Wants to Make a Challenge in Experienced Field, President Says on Licensed Cell Therapy
December 9, 2016
- Nippon Kayaku Wins Reversal in Elplat Patent Suit
December 9, 2016
- Keytruda Launch Planned in Early Next Year: MSD Japan Chief
December 9, 2016
- Pfizer’s “Established” Pharma Business Expands to “Essential Health” to Include New Drugs, Copromoted Products
December 9, 2016
- Ethical Drug Sales Tumble 12.2% in October: Crecon Report
December 8, 2016
- Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
- Heike Prinz to Become 1st Female President of Bayer Yakuhin
December 7, 2016
- Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
- Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
December 6, 2016
- Kaketsuken Wraps Up Blanket Re-Inspection, Says There’s No Quality or Safety Concern
December 6, 2016
- GSK Won’t Invest in Aspen Japan
December 6, 2016
- Toyama Chemical Begins Japan PIII for Macrolide Antibiotic
December 6, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…